Kura Oncology, Inc. (KURA)
12.89
+0.24
(+1.90%)
USD |
NASDAQ |
Sep 01, 16:00
12.88
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Research and Development Expense (Annual) : 251.07M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 251.07M |
| December 31, 2024 | 169.97M |
| December 31, 2023 | 115.24M |
| December 31, 2022 | 92.81M |
| December 31, 2021 | 84.72M |
| December 31, 2020 | 60.40M |
| Date | Value |
|---|---|
| December 31, 2019 | 47.83M |
| December 31, 2018 | 46.79M |
| December 31, 2017 | 26.43M |
| December 31, 2016 | 20.40M |
| December 31, 2015 | 17.51M |
| December 31, 2014 | 2.653M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Inovio Pharmaceuticals, Inc. | 52.79M |
| Fortress Biotech, Inc. | 11.90M |
| Syndax Pharmaceuticals, Inc. | 258.78M |
| Spero Therapeutics, Inc. | 38.47M |
| Gossamer Bio, Inc. | 174.07M |